01 Multiplex Chemiluminescence Assays The chemiluminescence immunoassay market analysis indicates that multiplex chemiluminescence immunoassays are gaining traction as laboratories seek to obtain broader diagnostic information from limited patient samples. Multiplex assay formats enable the simultaneous measurement of multiple biomarkers within a single test, using distinct capture reagents and analyte-specific detection systems to assess several disease indicators in one analytical workflow. This capability is supporting the expansion of multi-analyte test panels for oncology, infectious diseases, and autoimmune disorders, while reducing sample consumption, limiting repetitive testing, and improving laboratory throughput.
02 AI-Enabled Immunoassay Analysis Increasing volumes of laboratory data are supporting the integration of artificial intelligence into chemiluminescence immunoassay platforms. Machine learning algorithms can assist with signal interpretation, quality control, abnormal-result identification, and instrument performance monitoring. This development is encouraging manufacturers to combine automated analyzers with intelligent software capabilities, supporting more consistent result analysis and streamlined laboratory workflows.
April 2026 Roche Diagnostics expanded its Elecsys® chemiluminescence immunoassay portfolio by introducing new assays for oncology and infectious disease diagnostics on the cobas platform.
February 2026 Abbott Laboratories launched next-generation ARCHITECT chemiluminescence immunoassays with improved sensitivity and faster turnaround times for hospital laboratories.
October 2025 Siemens Healthineers expanded its Atellica® IM Analyzer menu with additional chemiluminescent immunoassays supporting endocrine, cardiac, and autoimmune disease testing.